Kamada
Pharmaceutical Development by Using a Unique Protein Purification Technology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | $60.0m | Private Placement non VC | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (22 %) | 25 % | 10 % | 13 % | 2 % | 9 % | 6 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 5 % | 8 % | 16 % | 17 % | 23 % | 23 % | 22 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (2 %) | (2 %) | 6 % | 9 % | 11 % | 12 % | 15 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 11 % | 10 % | 10 % | 9 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Kamada Ltd. is a biopharmaceutical company specializing in the development, production, and commercialization of plasma-derived protein therapeutics. Founded in 1990 and headquartered in Rehovot, Israel, Kamada operates in the global healthcare market, primarily serving patients with rare and serious conditions such as pulmonary emphysema, liver disease, and cytomegalovirus (CMV) infections. The company is publicly traded on NASDAQ and the Tel Aviv Stock Exchange under the ticker symbol KMDA.
Kamada's core business revolves around its proprietary technology for the extraction and purification of proteins from human plasma. This technology enables the company to produce a range of therapeutic products, including its flagship product, Glassia, an intravenous treatment for Alpha-1 Antitrypsin (AAT) deficiency. AAT deficiency is a genetic disorder that can lead to severe lung and liver diseases. Kamada also offers KamRAB, a rabies immunoglobulin, and is developing additional products targeting unmet medical needs.
The company's business model is built on a combination of direct sales and strategic partnerships. Kamada generates revenue through the sale of its products to hospitals, clinics, and healthcare providers, as well as through licensing agreements and collaborations with other pharmaceutical companies. For instance, Kamada has a long-standing partnership with Takeda Pharmaceuticals for the distribution of Glassia in the United States.
Kamada's growth strategy focuses on expanding its product portfolio, enhancing its manufacturing capabilities, and entering new markets. The company is also investing in research and development to advance its pipeline of innovative therapies, which includes treatments for graft-versus-host disease (GVHD) and COVID-19.
Keywords: biopharmaceuticals, plasma-derived, protein therapeutics, AAT deficiency, Glassia, KamRAB, rare diseases, strategic partnerships, global healthcare, innovative therapies.